The FDA grants fast-track designation to Galectin Therapeutics' (GALT) GR-MD-O2 treatment for treating non-alcoholic steatohepatitis (NASH) with hepatic fibrosis, commonly known as fatty liver disease with advanced fibrosis. It's a condition associated with obesity and affects 9-15M people in the U.S., including children.
GR-MD-O2 is in Phase I trials
"Our preclinical data has shown that GR-MD-02 has robust treatment effects in reversing fibrosis and cirrhosis," says CEO Peter Traber. (PR)